Percutaneous implantation has already been used clinically and is a great option for treating young patients. The use of autologous tissue-engineered valved stents might solve the problem of degeneration and limited durability of biological heart valves.
Introduction
Pulmonary valve regurgitation with late ventricular dysfunction after the repair of tetralogy of Fallot is a well-known problem. Treatment 1 using transannular patch augmentation of the right ventricular outflow tract (RVOT) is usually followed by severe complications such as pulmonary valve regurgitation with RVOT dysfunction. The Contegra conduit induces a neointimal proliferation at the level of the pulmonary anastomosis. This frequently leads to a high degree of supravalvar stenosis. 2 Furthermore, clinical implantation of decellularized xenograft valves results in early failure. 3 The use of an endovascular pulmonary valved stent was introduced clinically by Bonhoeffer et al. 4, 5 So far, this procedure represents an enormous advantage for young patients by avoiding one of the re-operations. The well-established bovine jugular vein valves used are glutaraldehyde-fixed, xenogeneic heart valves prone to degeneration and require later re-interventions and/or re-operations. 3 With the currently available valved stents and devices, it is not possible to treat all affected patients. Wide, mildly regurgitant or severely calcified and kinked RVOTs are not suitable for percutaneous therapy up to now. To overcome these problems, new stent designs (especially self-expanding stents) and different operative and interventional approaches are needed and are being analysed. 6 -8 The use of tissue engineering could provide one potential pathway to overcome these present limitations of heart valves in general. 9 Tissue-engineered heart valves require neither anticoagulation nor immunological reaction measures. The tissue-engineered valves have unique viability characteristics and the ability to grow and remodel.
Our group demonstrated the feasibility of implanting a completely percutaneous pulmonary valved stent into an ovine model using a selfexpanding nitinol stent. 7, 8 The continuously exerted radial force of the self-expanding nitinol stents and their high flexibility assure a geometric adaptation to anatomical and tissue property changes.
The overall goal of this study was to evaluate the function of the autologous tissue-engineered heart valve after percutaneous implantation of a nitinol valved stent.
Methods
The general approach to cell isolation, culture, and seeding, as well as the basic decellularization procedure, was described in detail previously. 6 In this study, we analysed nine pulmonary heart valves. Animals received humane care in accordance with the 'Principles of Laboratory Animal Care' and the 'Guide for the Care and Use of Laboratory Animals' (National Institutes of Health, Publication 85 - 23, revised 1985 ). An ethical committee on animal research at Kiel University approved the protocol.
Valve and submucosa harvest
Porcine pulmonary heart valves and small intestinal submucosa were obtained from a local slaughterhouse. Pulmonary valves were excised and freed of adherent fat and most of the myocardium, leaving only a thin layer of subvalvular muscle tissue and the pulmonary artery. After immediate dissection and antimicrobial incubation, valves were trimmed (removal of sinus and most of the muscular ring) to fit into the deployment catheter. Segments of porcine small intestine (20 cm in length) were cleaned by thoroughly washing with PBS (Invitrogen), followed by incubation in povidone-iodine solution (Mundipharma, Limburg, Germany) for 15 min. Decontaminated segments were repeatedly washed with PBS, and the mucosa and any connective tissue were removed mechanically. The remaining small intestinal submucosa was transferred into PBS containing an antibiotic solution (1.2 mg of amikacin, 3 mg of flucytosin, 1.2 mg of vancomycin, 0.3 mg of ciprofloxacin, and 1.2 mg of metronidazol in 1 mL of aqua ad inject) and stored at 48C for 48 h.
Valved stent design
Radially self-expanding nitinol stents (Nitinol Devices and Components, Inc., Fremont, CA, USA) were used in the present study. Bare stents were 28 mm in length and 22 -29 mm in diameter when fully expanded at 378C. The inside of the nitinol stent was covered with acellular porcine small intestinal submucosa, and the valve was sutured into the covered stent.
Decellularization and reseeding procedure
The entire construct (stent with small intestinal submucosa and implanted valve scaffold) was washed for 30 min at room temperature in povidoneiodine solution and sterile PBS, followed by another overnight incubation at 48C in an antibiotic solution (as above). After decontamination, the valves were placed in a solution of 0.05% trypsin and 0.02% EDTA (Biochrom AG) at 378C and 5% CO 2 for 12 h during continuous 3D shaking. After the removal of the trypsin -EDTA, the constructs were washed with PBS for another 24 h to remove residual cell detritus. The decellularized matrices were immediately processed for subsequent cell seeding.
A 5 cm-long segment of the recipient ovine carotid artery was removed under sterile conditions. Endothelial cells (ECs) were obtained using 0.2% collagenase A (Roche Diagnostics GmbH, Mannheim, Germany) and cultured on a 1% gelatin-coated (gelatine type A; Sigma-Aldrich Chemie GmbH, Munich, Germany) 24-well plate (Nunc GmbH, Wiesbaden, Germany) in a cell-culture medium (M199-medium, 1% penicillinstreptomycin, 10% foetal calf serum, and recombinant human fibroblast; Peprotech, Hamburg, Germany).
The ovine vessel wall segments were minced into 1 mm 2 pieces, distributed onto a six-well plate, and cultured in a cell-culture medium. After moving the myofibroblasts (MFs) onto culture dishes, cells were cultured in gelatin-pre-coated flasks. Both cell populations were incubated at 378C and 5% CO 2 and serially passaged with trypsin-ethylenediamine tetraacetic acid. A porcine scaffold was seeded with a mix of ovine fibroblasts and ovine smooth muscle cells (MFs) isolated from the carotid artery. These seeded valved stents were kept in a dynamic bioreactor for 16 days and finally seeded with ECs for 4 days.
Implantation procedure
For implantation, the construct was folded carefully and inserted into a modified commercially available delivery system. 8 Through a 22 French sheath positioned in the right femoral vein, the 20 French delivery system was inserted and the autologous tissue-engineered valved stent was successfully positioned on top of the native pulmonary valve under fluoroscopic control as described previously. 8 The sheep received Ketanest (2%) and propofol (2%) for sedation and then Cefuroxin (100 mL), heparin (5000 IU), and protamin (5000 IU) during implantation, finally at the end of the study, Rimadyl (1 mL). For 1 week, the sheep received the antibiotic Baytril (10%). Beforehand, the size of the native valve was measured using angiography. Four weeks after implantation, animals underwent re-angio with subsequent stent explantation followed by post-mortem investigation and processing for histology and immunohistochemistry.
Angio-and echocardiography
An angiography unit (Optimus M 200, Philips Medizin Systeme, Hamburg, Germany) was used for fluoroscopic assessment of the position and function of the tissue-engineered valves. Supravalvular angiography was performed for 30 min and 4 weeks after implantation. 8 Transthoracic echocardiography (TTE) was performed at 2 weeks of follow-up with the Ultrasound System Five (Vingmed Sound, Horten, Norway) using a multiplane 2.5 MHz transducer probe. The echocardiographic probe was applied at the right hemithorax between the fifth and sixth intercostal space. Echocardiographic evaluation of the tissue-engineered valve status was performed using M-mode, 2D, colourflow, pulsatile and continuous-wave Doppler. TTE was used for standard longitudinal and cross-sectional views and was recorded, stored, and analysed offline by an experienced investigator (K.I.). Maximum velocities across the pulmonary valve were calculated by a continuous-wave Doppler imaging transducer. Semi-quantitative assessment from grade 0 to 4 of pulmonary regurgitation (0 absence, 1+ trivial, 2+ mild, 3+ moderate, 4+ severe) was based on the length and width of the regurgitant jet and the distance that it reached into the RVOT on the parasternal shortaxis view. The transvalvular pressure gradient was determined using the Bernoulli equation.
Haemodynamic measurements
Arterial pressure, right ventricular pressure (systolic, diastolic, and mean), and pulmonary artery pressure (systolic, diastolic, and mean; use of a micro-tip Millar Catheter, Millar Instruments, Inc., Houston, TX, USA) were recorded using Haemodyn-Software (Hugo Sachs Electronics, Hugstetten, Germany). The software calculates the maximum of the first derivative of the ventricular pressures (dp/dt max ) as an indicator for the contractility and its minimum (dp/dt min ) as an indicator for the relaxation behaviour. Times of pressure measurements of the right ventricle were: before, 5 min after implantation, and at 1 month follow-up.
Computer tomography and mammogram
Computer tomography (CT) analysis was performed with a multislice CT scanner (Siemens, Erlangen, Germany) to evaluate the positioning of the valved stent after 4 weeks (Siemens MDCT Somatom 64 slice min. Increment 0.6 cardiac-protocol with retrospective triggering, Testbolus 5 mL Imeron 4 in RA Bolus 1 mL Imeron 400/kg reconstruction MIP 0 -100 in 5% steps). The mammogram was carried out with a Hologic Selenia device (Medicor, Inc., Kerpen, Germany). A 1.8-fold enlargement with a molybdenum filter was used.
Post-mortem investigation
The following parameters were examined by macroscopic analysis of the pulmonary heart valved stents: signs of thrombosis, paravalvular leakage, calcification, and ortho-or heterotopic position; surface and morphology of leaflets; and in-growth, damage or fracture of stent, and an in vitro testing. The native pulmonary valve was analysed for thrombi, inflammation, calcification, or rupture.
In vitro testing
Fluid passing into the valved stent in the appropriate direction filled the pouch-like valvular sinuses delimited by each of the leaflets. In this way, the valve leaflets coapted inside the segment of the conduit, thereby providing effective valve closure. Fluid flow in the opposite direction was not restricted (bench test), competence was tested before and after explantation.
Histology and immunocytochemistry
The explanted valved stent was analysed macroscopically and radiographically by mammogram and then the stent was fixed in 4% formalin. Each leaflet was separated and carefully removed from the stent. One leaflet was processed for histology. Specimens were fixed for 72 h at 208C in 4% paraformaldehyde in 0.1 mol/L cacodylate buffer, pH 7.4. They were washed in tap water for 2 h, dehydrated in graded alcohol, and finally embedded in paraffin (Merck, Darmstadt, Germany). Sections (1 -2 mm) of each tissue sample were deparaffinized and rehydrated. For general morphology, serial sections were stained with haematoxylineosin (H&E) stain (cellular components and nuclei) and Movat pentachrome. For the identification of ECs on the tissue surface, factor VIII-related antigen staining and endothelin staining (PECAM-1) were conducted. 6 To identify MFs, a-actin-related antigen staining was performed, and to identify apoptotic cells, caspase-3 staining was performed. To check for inflammation, CD68 antibody staining was used, and for calcification von Kossa staining. Sub-and supravalvular and the annular regions and the edge of the leaflets were analysed. Sections were analysed and documented using brightfield light microscopy (Axiovert; Zeiss; Jena, Germany). In addition, one leaflet of the reseeded valve (n ¼ 6) was separated and processed for histology, as described above.
Statistical analysis
Values are presented as mean + standard deviation. Data were analysed based on the paired Student's t-test to compare related data for normally distributed data; non-normally distributed data were analysed by the SPSS 10.1 software (SPSS, Inc., Chicago, IL, USA). The P-values ,0.05 were considered statistically significant.
Results
This procedure was performed in nine juvenile sheep weighing 36.0 + 7.0 kg. The mean diameter of the native pulmonary annuli were 22.2 + 4.4 mm (range 17.0-29.3 mm) as revealed by angiography. Implanted valved stents with a maximal outer diameter between 20 and 25 mm were then matched and used.
The total procedure time was 15 + 3 min, and the fluoroscopy time was 5 + 1 min. Two sheep showed endocarditis and were excluded from this study. Afterwards, i.v. applications of antibiotics were routinely given pre-operatively, which we did not do in the first two cases. In the other animals, no endocarditis was seen.
In vitro analysis
Histological analysis of the decellularized valve tissue sections stained with H&E indicated that treatment with trypsin-EDTA for 12 h followed by a 24 h washing with PBS converted native porcine pulmonary valves into a cell-free scaffold ( Figure 1A and C) .
A confluent EC lining of the leaflets with large rounded nuclei and a strong granular perinuclear immunocytochemistry with PECAM-1 was revealed after the reseeding of the pulmonary valve prior implantation ( Figure 1B , D, and E).
Angio-and echocardiography
Angiographic observation indicated correct orthotopic positioning of each valved stent in six sheep at the time of implantation and at 1-month follow-up ( Figure 2 ). One valved stent demonstrated a heterotopic position. Angiography revealed no regurgitations after 4 weeks and showed competent valved stents in all subsequent sheep. One-month angio-and echocardiography demonstrated good opening and closing characteristics of the implanted valves. Valve competence was maintained during follow-up, with 100% having no or trivial pulmonary regurgitation under echocardiographic control. The incidence of perivalvular leakages was zero. The average Doppler mean gradient was 4 + 3.5 mmHg after 4 weeks.
Haemodynamic measurements
During the deployment procedure, rhythm disturbances occurred in all animals. In addition, one sheep developed atrial fibrillation, which was converted pharmacologically into sinus rhythm. The peak-to-peak gradient across the valved stents was 2.3 + 1.1 mmHg initially, and 5.2 + 2.7 mmHg at follow-up (P , 0.02). The maximum of the first derivation of both ventricles and its minimum of both ventricles were unchanged compared with baseline at different time points. Haemodynamic data are given in Table 1 .
Cardiac CT and mammogram
The mammogram of the stent showed mild annular calcification in the investigated sheep (four out of seven; Figure 3B and C ). Cardiac CT data demonstrated orthotopic position of the stent in all analysed sheep (five out of five; Figure 4 ), whereas in one sheep, a heterotopic position was already found in the echocardiographic analysis and has therefore consecutively not been investigated by CT.
Post-mortem investigation
Macroscopic analysis of the pulmonary heart valved stent demonstrated optimal orthotopic positioning in six sheep and heterotopic position in one sheep ( Figure 5A and B) . The stent was found directly beneath the annular plane. Macroscopic analysis of the leaflets showed smooth surfaces with no thrombus formation ( Figure 5C ). No paravalvular defects of the seven valved stents were observed. The valved stents were flexible and the leaflets were thin without hardenings. A slight fibrous overgrowth was limited to the outflow unit of the valved stents. Cardiac structures were intact and no macroscopic damage was observed. Figure 5B demonstrates that the native valve was completely pushed aside and indicated no signs of inflammation, thrombi, calcification, or rupture (as seen in all animals).
Histology and immunocytochemistry
H&E staining made general morphology of the leaflets visible ( Figure 6A) . The Russel-Movat pentachrome staining ( Figure 6B ) made the physiological valve structure visible with the preservation of arterialis, fibrosa, spongiosa, and ventricularis, and no apparent disruptions of the leaflet. A confluent EC lining of the leaflets displayed typical cobblestone-like morphology ( Figure 6C) overlaying the smooth muscle cells. These cells expressed endothelin-1 (PECAM-1), indicating an endothelial character. Immunohistochemistry demonstrated strong expression of a-smooth muscle actin and an inward growth into the leaflets ( Figure 6D ). There were no significant differences between thickness, layer formation, cellularitiy, and various cell types observed.
Anti-CD68 staining confirmed no signs of inflammation in all animals ( Figure 6E ). von Kossa staining revealed mild calcification in four of seven sheep ( Figure 6F) in the annular region, whereas the other areas did not reveal any calcification. Caspase-3 staining demonstrated no apoptotic cell bodies in the four analysed valve regions after 4 weeks.
Discussion
Endovascular pulmonary valved stent implantation represents an enormous advantage for young patients to avoid one of the re-operations, i.e. after a correction of tetralogy of Fallot and is also an upcoming alternative or additional option for a successful surgical scheme. Bonhoeffer and colleagues successfully performed 155 procedures with no early deaths and only 4 procedural complications. 10 The survival rate of these 155 patients after a follow-up of 83 months was 96.9%. The advantages of percutaneous/minimally invasive procedures are obvious (i.e. smaller or no incisions, less post-operative pain, shorter hospital stay, and cost savings). However, tissue engineering might offer an additional potential pathway to overcome the present limitations of glutaraldehyde-preserved, biological heart valves. 9 All commercially available grafts for RVOT reconstruction necessitate subsequent replacement in paediatric patients due to their inability to grow and remodel, and their strong calcification over time. 11 To our knowledge, this is the first study analysing tissue-engineered valved stents after percutaneous valved stent implantation.
Overcome of graft failure
To reconstruct the RVOT in congenital heart disease cases, surgeons normally use human allograft valves despite their induced immunological response from partially preserved cell viability that can possibly cause graft failure. 12 Concerning the RVOT reconstruction, one author reported a strong reduction of immunological reactions by using decellularized human allograft valves in a long-term study over 18 months. In contrast, they did not see this reduction in the group using cryopreserved human allograft valves. 13 Another research group demonstrated in an animal model that decellularized pulmonary heart valves had an enormous potential for thrombogenicity and pathological neointima formation compared with the in vitro pre-endothelialized grafts. 14 Other groups analysed decellularized xenografts in clinical studies and observed early graft failure. 3, 15 This might be caused by preserved matrix immunogenicity of the porcine scaffold. On the basis of these results, it seems necessary to repopulate decellularized biological valve scaffolds with autologous cells to obtain good long-term viability and durability of these tissue-engineered valves.
Anchorage of valved stents
Therefore, we used decellularized xenograft matrices and reseeded them with autologous endothelial and smooth muscle cells. These bioengineered valved stents were then percutaneously implanted into the pulmonary position of sheep. In all but one sheep, we found an orthotopic position of the valved stent at the time of implantation by angiography and explantation after post-mortem investigation (n ¼ 6). Unfortunately, in one sheep, the stent was in a heterotopic position at the time of explantation. Nevertheless, during stent implantation, fluoroscopy revealed orthotopic positioning in all sheep. Afterwards, one of the stents must have migrated and was found in the subannular region of the RVOT at the time of explantation. This problem might be solved through a better alignment of the stent as a result of a more precisely designed 3D anatomic structure better adapted to the morphology of the RVOT and pulmonary annular region at the time of implantation. The help of a pre-operative CT will provide the necessary data needed to construct an individualized stent (unpublished results 2009). Computeraided design combined with rapid prototyping can be used to create accurate models of the RVOT and pulmonary trunk. 16, 17 
Nitinol stent
The ability of the soft nitinol stent to adapt and to align to the surrounding RVOT tissue could be superior compared with steel or platinum stents. 17 The newly described technique has the advantage of implanting valved stents also in patients with a sole regurgitation of the valve. This is a major advantage of these self-expanding stents. In addition, autologous tissue-engineered valved stents have the possibility to grow in contrast to, for example, bovine jugular vein valves in balloon expanded stents. In the case of a bioabsorbable stent, not only the valve might grow, but also the stent restriction is no longer present after a certain amount of time. This study indicated that the right ventricular pressures and the pulmonary artery pressure were mildly decreased compared with pre-operative data, whereas no significant transvalvular gradients were revealed in our tissue-engineered valves after the 4-week follow-up.
Allo-, xeno-, or homografts
In another study which was performed in vitro, they showed that it is better to use allografts than xenografts. 18 This group used porcine and human heart valves from a homograft bank. The cells grew better on the homograft leaflet than on a xenograft leaflet. The advantages of both grafts are no necessity of anticoagulation and high biocompatibility. In contrast, in this study, a xenogeneic matrix and a decellularized porcine pulmonary heart valve were used and seeded with endothelial and smooth muscle cells from the carotid artery of a sheep. The reason we did not use a homograft or an ovine allograft is that in a later human setting we would not have enough homografts available for mounting and implanting autologous cells not only into the pulmonary position. Owing to the possible logistic problems associated with those grafts, we used decellularized xenografts instead.
Concept of tissue engineering
We used cells from a carotid segment of a sheep and implanted the tissue-engineered heart valve into the same sheep. After 4 weeks, the valved stent was explanted and the leaflets were processed for histology. This concept of tissue engineering is based on the usage of decellularized biological matrices, so that the removal of dissimilar cellular components might reduce immunological reactions. Histology confirmed an in-growth of the seeded cells into the leaflet and no signs of inflammation. However, we found mild calcification spots mainly in the annular region of some of the leaflets. It is unclear whether the seeded tissue (endothelial and smooth muscle cells) is still from the original valve implant, is derived from the native pulmonary artery, or is an exotic grown into the new valve. This uncertainty has motivated us to differently mark both autologous cell layers by a lentivirus expression system in our future studies. 19 
Histological results
The immunohistochemistry revealed a strong expression of a-smooth muscle actin in smooth muscle cells and von Willebrand and of PECAM-1 in ECs. Moreover, H&E staining ( Figure 6A ) revealed a confluent in-growth of ovine MFs into the valve leaflets, revealing a picture comparable with that of native tissue, which was also demonstrated in our preceding in vitro studies. 6, 20 In these foregoing studies, cell proliferation (before implantation) was ascertained with a CellTiter non-radioactive cell proliferation assay and measured with the 96-well plate enzyme-linked immunosorbent assay reader for metabolic activity. The inside part of the nitinol stent was completely covered with a porcine mucosa. We have already shown 6 that a small intestinal submucosa covering of the inside of a pulmonary valved stent can prevent stent strut-related damage. The only noncovered area of the stent was the outside of the stent: the outside stent struts made imprints of the stent into the endothelium ( Figure 5B) . No thrombi or enhanced fibrotic areas in the outside areas of the stent struts were assessed.
Calcification
In addition, good functioning of all leaflets was confirmed by angiography, post-mortem investigation, and histology. However, microcalcification was observed at the neo-annulus by mammogram and von Kossa staining in four of seven animals ( Figures 3B and C, and 6E ). This calcification might be induced by an immunological reaction against the leftover antigens of the xenograft. The reason why we did not find calcifications in all analysed areas and in the additional three animals of the overall cohort remains unknown. This is still an unanswered question regarding the avoidance of microcalcification. Different anticalcific methods were experimentally and clinically used. They can be divided into different groups: modifications to glutaraldehyde-processed tissue and non-glutaraldehyde-processed tissue. Examples of modified glutaraldehyde-processed tissue methods are sodium dodecyl sulphate and Tween-80 as well as ethanol pre-incubation to remove phospholipids. Epoxy compounds, dye-mediated photo-oxidative reactions, and carbodiimide compounds are examples of non-glutaraldehyde-processed tissue methods. In general, the calcification process of bioprosthetic valves is very complex and diverse calcification processes are often described. 21 
Clinical use
Tissue-engineered valves with autologous cells have already been used clinically. These cells might have the potential to remodel and grow so that those valves can grow in the adolescent humans. 22 In this human study, they isolated mononuclear cells from children's peripheral blood, seeded those cells on a decellularized human pulmonary valve (acellular allograft matrix), and placed it into a bioreactor. During a conventional heart operation, the old calcified valve was resected and the new tissue-engineered one implanted into the children's heart with congenital pulmonary valve failure. Post-operatively, a mild pulmonary regurgitation was documented in the two analysed children. In the following 3.5 years, the pulmonary valve annulus diameter increased, the valve regurgitation mildly decreased, and no signs of valve degeneration have been observed so far.
Limitations
In contrast to this experimental technique, in humans at a later stage, cells should be isolated either from bone marrow, or better, from peripheral blood-derived cells to obtain a pure population of ECs and MFs. Different limitations of this study remain to be analysed: evaluation of the optimal cell source for cell seeding of the conduits and of the potential immunological barrier of the porcine extracellular matrix in humans. Additionally, the imminent infection risk over a long time period also should be stated. 23, 24 Also re-operations are necessary several times in children due to the fact that the valved stent does not have the possibility to grow yet. Using biodegradable stents might help allow these valves grow over time. Another idea is to use specific DNA-aptamers as capture molecules for endothelial progenitor cells in vivo. 25 In order to further reduce the outer diameter of the overall delivery system of valved stents in general, one can use polyurethane as a material for the production of leaflets. These valves have a thickness of 100-150 mm and can be used in a valved stent which fits into a 14F delivery system. The implantability of a new polyurethane valved stent over a 4-week observation period with good results has been already shown by our group. 26 Pulmonary valved stent implantation is guided by the angiography during the implantation procedure in clinical cases. Nevertheless, a less X-ray-dependent guidance will be possible in the near future: MRI-guided pulmonary stent implantations were done already. This method will substantially reduce the X-ray exposure of those patients. However, the procedure is still very difficult to perform under such guidance. Horvath et al. demonstrated that real-time magnetic resonance imaging is an excellent option for transapical aortic valved stent implantation on the beating heart. 27 Another good imaging assistance for the pulmonary valve placement could be the use of live 3D echocardiography, which could clearly show the right and left ventricles and atrium. For mitral and aortic valve replacement, it is a good alternative to use imaging assistance. For pulmonary valve replacement, there are many limitations, but this is still under investigation. 28 
Conclusion
The present study demonstrates successful percutaneous implantation of tissue-engineered pulmonary heart valved stents with good valve function after a 4-week period. Although the data are very promising, there is still an unanswered question regarding the avoidance of calcification. Additional mid-and long-term data will further demonstrate the durability of these valves. This implantation of autologous tissue-engineered valved stents will become a valid future option in adolescents.
